** indicates a classic citation as deemed by Science Citations

Gorman, CM and Bullock C. (2000) Site-specific integration techniques for achieving sustained gene expression. Current Opinion in Biotechnology in press.

Bullock C. and Gorman, CM. (2000) CAT as a reporter. Methods in Enzymoogy, in press

McClarrinon, M, Gilkey,L, Watral, V, Fox, B, Bullock, C, Fradkin, L, Liggitt, D, Roche, L, Bussey, LB and
Gorman, CM (1999) Transient transgenesis using lipid-DNA delivery. DNA & Cell Biology DNA Cell Biology. 18:533-547.

Gorman, CM (1998) Aerosol delivery of lipid:DNA complexes to lung of Rhesus monkey. Pharm. Res . 15:671-679.

Gorman, CM, Aikawa, M., Fox, B., Fox, E., Lapuz, C., Michaud, B., Nguyen, H., Roche, E., Sawa, T and Weiner-Kronish, JP (1997) Efficient in vivo delivery of DNA to pulmonary cells using the novel lipid EDMPC. Gene Therapy 4:983- 992.

Pietras Richard J, Arboleda Jane, Reese David M Wongvipat Nancy, Pegram Mark D Ramos Lillian, Gorman, CM,  Parker Malcolm G, Sliwkowski Mark X, Slamon Dennis J. (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10:2435-2446.

Presta L, Shields R, O'Connell L, Lahr S, Porter J, Gorman CM, Jardieu P. (1994) The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269:26368-26373.

Matthews David J, Goodman Laurie J, Gorman, CM, Wells James A. (1994) A Survey of furin substrate specifically using substrate phage display. Protein structure Functions. Protein Science 3:1197-1205.

Goodman Laurie J, Gorman, CM. (1994) Autoproteolytic activation of the mouse prohormone convertase MPC1. BBRC 201:795-804.

Groskreutz D, Sliwkowski M, Gorman, CM. (1994) Constitutive secretion of active insulin by epithelial cells. JBC 269:6241-6245.

Presta L G, Lahr S J, Shields R L, Porter J P, Gorman, CM, Fendly B M, Jardieu P M. (1993) Humanization of an antibody directed against IgE. Journal of Immunology 151(5):2623-2632.

Marriot D, Gillece-Castro B, Gorman, CM (1992) Prohormone Convertase-1 will process pro-relaxin, a member of the insulin family of hormones. Mol. Endo. 6:1441-1450.

Schmelzer C H, Burton L E, Chan W-P, Martin E, Gorman, CM, Canova-Davis E, Ling V T, Sliwkowski M B, McCray G, Briggs J A, Nguyen T H, Polastri G. (1992) Biochemical characterization of recombinant human nerve growth factor. J. of Neurochem. 59:1675-1683.

Carter P. Presta L, Gorman, CM, Ridgway J, Henner D, Wong W, Rowland A, Kotts C, Carver M, Sheppard M. (1992) Humanization of an anti-p 185 Her2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. 89:4285-4289.

Paborsky L, Caras I, Fisher K, Gorman, CM. (1991) Lipid association, but not the transmembrane domain, is required for tissue factor activity. J. Biol. Chem. 226:21911-21916.

Choi T, Huang M, Gorman, CM, Jaenisch R. (1991) A generic intron increases gene expression in transgenic mice. Mol. and Cell. Biol. 11:3070-3074.

Gorman, CM. (1990) Mammalian cell expression. Current Opinion in Biotechnology 1:36-47.

Paborsky L. Fendly B M, Fisher K, Lawn R, Marks B J, McCray G, Tate K, Vehar G, Gorman, CM. (1990) Mammalian cell transient expression of tissue factor for the production of antigen. Protein engineering 3 (6):547-553.

Huang M, Gorman, CM. (1990) The simian virus 40 small t intron, present in many common expression vectors, leads to aberrant splicing. Molecular Cell Biology 10(4):1805-1810.

** Gorman, CM, Gies D, McCray G. (1990) Transient production of proteins using adenovirus transformed cell line. DNA protein engineering techniques 2 (1):3-10.

Huang M, Gorman, CM. (1990) Intervening sequence increases efficiency of RNA 3' processing and accumulation of cytoplasmic RNA.  Nucleic Acids Reg. 18(4):937-47.

** Pritchett D B, Sontheimer H, Gorman, CM, Kettenmann H, Seeburg P, Schofield P. (1988) Ligand-gating and allosteric potentiation of human GABA receptor subunits in a transient mammalian cell expression system. Science 242:1306-1308.

Eaton D L, Wood W, Eaton D, Hass P, Hollingshead P, Wion K, Mather J, Lawn R, Vehar G, Gorman, CM. (1986) Construction and characterization of an active Factor VIII variant lacking the central one-third of the Molecule. Biochemistry 25:8343-8347.

** Gorman, CM, Rigby P W J, Lane D P. (1985) Negative regulation of viral enhancers in undifferentiated embryonic stem cells. Cell 42:519-526.

** Gorman, CM. (1985) High efficiency gene transfer. DNA Cloning a Practical Approach. ed. Glover D M, IRL Press.

Gorman, CM, Lane D P, Rigby PW J. (1984) High efficiency gene transfer into mammalian cells. Phil. Trans. R. Soc. Lond. B307:343-346.

** Gorman, CM, Howard B, Reeves R. (1983) Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 11:7631.

** Gorman, CM, Padmanabhan R, Howard B. (1983) High efficiency DNA-mediated transformation of primate cells. Science 221:551-553.

** Gorman, CM, Merlino G, Willingham M, Pastan I, Howard B. (1982) The Rous sarcoma virus LTR is a strong promoter in a variety of cell types when introduced by DNA mediated transfection. Proc. Natl. Acad. Sci. USA 79:6777-6781

**Laimons L, Khoury G, Gorman, CM, Howard B, Gruss P. (1982) Host specific activation of transcription by tandem repeats from SV40 and Maloney sarcoma virus. Proc. Natl. Acad. Sci. USA 79:6453-6457.

** Gorman, CM, Moffat L, Howard B. (1982) Recombinant genomes that express chloramphenicol acetyltransferase in mammalian cells. Mol. Cell. Biol. 2:1044-1051.

Cori Gorman, PhD, MBA

With twenty-five years experience in the biotechnology industry, Dr. Gorman has worked in all aspects of the biotechnology industry, including raising capital, strategic planning and developing infrastructure. She has helped early stage biotechnology companies raise over $ 80 million (federal funds and VCs) and has closed over 25 partnerships in a corporate development capacity. She has used this experience to chair a number of sessions on business models and financing for early stage companies at BIO and Bio-Europe conferences. She has been a guest lecturer on the business of biotechnology at Yale and at Haas Business School, UC Berkeley. Under her vision, DNA Bridges Inc. has expanded its reach beyond the US into Europe and Australia.

Her experience in the biotechnology industry includes a ten-year period at Genentech where she helped to develop of a number of marketed products including Kogenate, Activase, Herceptin, Xolair, and Raptiva. Based on her work at Genentech, Cori is also recognized as a pioneer in the development of monoclonal antibody therapeutics and has co-authored 6 INDs. Upon leaving her position at Genentech, Cori co-founded two biotech start-ups, one of which, Valentis, went public.

Dr. Gorman has an outstanding record of achievement in basic research and drug development. Dr. Cori Gorman is an inventor on nine issued patents in the fields of gene expression and delivery and gene therapy and is recognized as one of the most highly cited people in her field in the last two decades. Dr. Gorman developed the CAT assay, which was the industry standard for more than fifteen years. Her scientific work has received over 10,000 citations

Cori has received several fellowships from such organizations as the American Cancer Society, the National Cancer Institute, the European Molecular Biology Organization and NATO.



Scientific work cited over 13,000 times, including nine classic citations

Recipient of American Cancer Society Fellowship

Recipient of NATO Fellowship

Recipient of European Molecular Biology Organization (EMBO) Fellowship

Outstanding Teaching Assistant Washington State University

Graduated Sigma Cum Laude University of Texas El Paso

One of the Top Ten Graduates University of Texas El Paso

"Cori Gorman has an extraordinarily high level of expertise, which was one of the critical factors in choosing her for this. When things come up again, she is the person I will go to."

- Senior scientist at a biotechnology company

An independent third party conducted a quality survey for DNA Bridges,Inc. The third party, in association with Dunn and Bradstreet, interviewed several clients. All clients stated that the costs met expectations and projects were competed on time.

DNA Bridges Patents